Product Description: Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody targeting to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD)[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Tulisokibart. IMGT/mAb-DB./[2]Feagan B G, Sands B, Siegel C A, et al. DOP87 The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study Results[J]. Journal of Crohn's and Colitis, 2023, 17(Supplement_1): i162-i164.
CAS Number: 2648504-55-4
Molecular Weight: N/A
Compound Purity: 95.00
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: TNF Receptor